Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
CA 2210294 C · Owner: Franchini, Genoveffa · Inventors: Paoletti, Enzo; Franchini, Genoveffa; Gallo, Robert C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Attenuated recombinant viruses containing DNA encoding an HTLV antigen such as HTLV env or HTLV1171, as well as methods and compositions employing the viruses expression products therefrom, and , antibodies generated from the viruses or expression products are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 16, 1996 and granted November 11, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 16, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 16, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.